Clinical trials: HBP
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
The purpose of this study is to investigate the effect of Atorvastatin on the pharmacokinetic properties of Telmisartan/S-amlodipine
- Trial name
- CKD-345 DDI (NCT01842230)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, Telmisartan 80mg and S-amlodipine 5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Pulmonary Arterial Hypertension
A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to see how much study drug is in the blood of children with pulmonary arterial hypertension (PAH) after dosing to establish the correct dose for further clinical research.
- Trial name
- NCT01484431
- Testing
- Tadalafil- Tablet or Oral suspension
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Hypertension, Diabetes
A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of…
- Trial name
- NCT00219102
- Testing
- aliskiren
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 336 people
- Sponsor
- Novartis
Hypertension, Early Diabetic Nephropathy
Antialbuminuric Effects of Valsartan and Lisinopril
Title: Antialbuminuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), open label, parallel group, 20 weeks follow-up.
- Trial name
- NCT00171600
- Testing
- VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
- Where
- Switzerland
- Volunteers
- 54 people
- Sponsor
- Novartis
Open Angle Glaucoma, Ocular Hypertension
Efficacy Study of Travoprost APS Versus TRAVATAN
A Multi-Center Double-masked Study of the Safety and Efficacy of Travoprost APS Compared to TRAVATAN in Patients with Open-angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00848536
- Testing
- Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution, Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
- Volunteers
- 371 people
- Sponsor
- Alcon Research
Non-operable Chronic Thromboembolic Pulmonary Hypertension
Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)
The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic…
- Trial name
- CTREPH (NCT01416636)
- Testing
- Treprostinil sodium
- Where
- 6 sites in Austria, Czechia and 2 more
- Volunteers
- 105 people
- Sponsor
- SciPharm SàRL
Obesity
BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients.
- Trial name
- NCT00603902
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 4,008 people
- Sponsor
- Eisai Inc.
Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with…
- Trial name
- UNISUS (NCT04273945)
- Testing
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg
- Where
- 274 sites in United States, Argentina and 40 more
- Volunteers
- 935 people
- Sponsor
- Actelion
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
The primary objective of this study was to compare the change in intraocular pressure (IOP) of three different doses of latanoprost (75, 100 and 125 ug/ml) to that of the marketed 50 ug/ml dose, in a dose ranging study.
- Trial name
- NCT01379144
- Testing
- latanoprost 75 ug, latanoprost 100 ug, latanoprost 125 ug
- Where
- 25 sites in Australia, Czechia and 6 more
- Volunteers
- 282 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Renal Insufficiency, Chronic
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
The purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney…
- Trial name
- INSPIRE-CKD (NCT04162366)
- Testing
- Aprocitentan 25 mg
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Hypertension
Xirtam H Combination In the Treatment of Hypertension Evaluation Study.
This is post-marketing observational study in which data on safety and effectiveness of Xirtam H will be collected from routine clinical practice.
- Trial name
- XCITE (NCT01219556)
- Testing
- Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
- Where
- India
- Volunteers
- 8,704 people
- Sponsor
- Bayer
Glaucoma, Ocular Hypertension
Survey of Patients Taking IOP-Lowering Eye Drops
Survey to assess perspectives of patients prescribed IOP-lowering eye drops at a single office visit.
- Trial name
- NCT02384772
- Testing
- Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- ForSight Vision5, Inc.
Hypertension
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
The purpose of this study is to evaluate the effects on blood pressure control, pulse wave velocity, as well as safety and tolerability of felodipine single or combine with other drugs in Chinese Hypertension patients.
- Trial name
- NCT02336607
- Testing
- Felodipine tablet (Plendil) alone, Felodipine tablet (Plendil)+Hydrochlorothiazide, Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)
- Volunteers
- 529 people
- Sponsor
- AstraZeneca
Hypertension (HTN)
QLS1410 in Participants With Uncontrolled Hypertension
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN).
- Trial name
- NCT07489612
- Testing
- Dose 1 of QLS1410, Dose 2 of QLS1410, Dose 3 of QLS1410
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pulmonary Arterial Hypertension
Absorption, Distribution, Metabolism and Excretion of BIA 5-1058
the purpose of this study is: to determine the rate and routes of excretion of BIA 5-1058 and the mass balance in urine, feces and exhaled air, after a single oral dose of 400 mg 14C labeled BIA 5 1058 containing 3.7…
- Trial name
- ADME (NCT04991181)
- Testing
- 400 mg BIA 5-1058
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Ocular Hypertension, Glaucoma
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma.
- Trial name
- NCT01033422
- Testing
- CF101
- Where
- 3 sites in Bulgaria, Israel
- Volunteers
- 89 people
- Sponsor
- Can-Fite BioPharma
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fed conditions
- Trial name
- NCT06744439
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Glaucoma, Retinal Disease
Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100
This study is a prospective comparative study to gather pilot agreement and precision data in normal subjects, subjects with glaucoma, and subjects with retinal disease.
- Conditions
- Glaucoma, Retinal Disease, Healthy
- Trial name
- OCT (NCT03505567)
- Testing
- KOWA OCT Bi-µ, Optovue iVue 100
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Essential Hypertension, Dyslipidemia
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of combination of Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with essential hypertension and dyslipidemia.
- Trial name
- NCT02166814
- Testing
- Fimasartan and Rosuvastatin, Fimasartan, Rosuvastatin
- Where
- 26 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.